AU2003274652A1 - Compounds, compositions and methods for modulating fat metabolism - Google Patents

Compounds, compositions and methods for modulating fat metabolism

Info

Publication number
AU2003274652A1
AU2003274652A1 AU2003274652A AU2003274652A AU2003274652A1 AU 2003274652 A1 AU2003274652 A1 AU 2003274652A1 AU 2003274652 A AU2003274652 A AU 2003274652A AU 2003274652 A AU2003274652 A AU 2003274652A AU 2003274652 A1 AU2003274652 A1 AU 2003274652A1
Authority
AU
Australia
Prior art keywords
compositions
compounds
methods
fat metabolism
modulating fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003274652A
Other versions
AU2003274652A8 (en
Inventor
Olivier Bousquet
Georges Gaudriault
Anne Goupil-Lamy
Itzik Harosh
Ahmet Kilinc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ObeTherapy Biotechnology SAS
Original Assignee
ObeTherapy Biotechnology SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObeTherapy Biotechnology SAS filed Critical ObeTherapy Biotechnology SAS
Publication of AU2003274652A1 publication Critical patent/AU2003274652A1/en
Publication of AU2003274652A8 publication Critical patent/AU2003274652A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
AU2003274652A 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism Abandoned AU2003274652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42031602P 2002-10-23 2002-10-23
US60/420,316 2002-10-23
PCT/IL2003/000860 WO2004037159A2 (en) 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism

Publications (2)

Publication Number Publication Date
AU2003274652A1 true AU2003274652A1 (en) 2004-05-13
AU2003274652A8 AU2003274652A8 (en) 2004-05-13

Family

ID=32176552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003274652A Abandoned AU2003274652A1 (en) 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism

Country Status (2)

Country Link
AU (1) AU2003274652A1 (en)
WO (1) WO2004037159A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060084845A (en) 2003-07-25 2006-07-25 이데닉스 (케이만) 리미티드 Purin nucleoside analogues for treating flaviviridae including hepatitis c
CA2548283A1 (en) * 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
EP1598354A1 (en) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
ITMI20041567A1 (en) * 2004-07-30 2004-10-30 Maycos Italiana Di Comini Miro "N-ACYLATED DERIVATIVES OF BICARBOXYLIC ACIDS WITH AMINO ACIDS AND WITH HYDROLYZED VEGETABLE PROTEINS AND THEIR APPLICATION IN COSMETIC, DERMO-PHARMACEUTICAL AND PHARMACEUTICAL PRODUCTS"
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
CA2608116A1 (en) 2005-05-10 2006-11-16 Intermune, Inc. Method of modulating stress-activated protein kinase system
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR20080016567A (en) * 2005-05-17 2008-02-21 쉐링 코포레이션 Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN1947717B (en) 2005-10-14 2012-09-26 卓敏 Method for treating neuronal and non-neuronal pain
JP5092753B2 (en) * 2006-01-06 2012-12-05 味の素株式会社 Gelling agent
PE20070854A1 (en) 2006-01-20 2007-09-10 Schering Corp HETEROCYCLES COMPOUNDS AS AGONISTS OF THE NICOTINIC ACID RECEPTOR
KR20090047391A (en) 2006-04-07 2009-05-12 데벨로겐 악틴게젤샤프트 Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
WO2007139497A1 (en) * 2006-05-30 2007-12-06 Aprea Ab Levoglucosenone derivatives for the treatment of disorders such as cancer, autoimmune diseases and heart diseases.
US20080009508A1 (en) * 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2164500B1 (en) * 2007-05-25 2013-12-04 Idogen AB The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
KR100881137B1 (en) 2007-08-07 2009-02-02 충남대학교산학협력단 New pig pheromonal compounds, their preparation method and a composite for estrus induction
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
KR101574332B1 (en) * 2008-06-17 2015-12-08 재단법인 한국파스퇴르연구소 Anti-infective compounds
UY32072A (en) 2008-08-26 2010-03-26 Boehringer Ingelheim Int TIENOPIRIMIDINS FOR PHARMACEUTICAL COMPOSITIONS
KR100883548B1 (en) * 2008-10-15 2009-02-13 충남대학교산학협력단 Pig pheromonal compounds, their preparation method and a composite for estrus induction containing it
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
FR2940611B1 (en) 2008-12-30 2012-01-13 Oreal ASSOCIATION OF MONOSACCHARIDES AND ADENOSINE AND ITS USE IN COSMETICS
UA112284C2 (en) * 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі 5-fluoro-pyrimidinone derivatives
PE20120689A1 (en) * 2009-08-07 2012-06-06 Dow Agrosciences Llc 5-FLUORO-2-OXOPYRIMIDINE-1 (2H) -CARBOXYLATE DERIVATIVES
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
FR2951639B1 (en) 2009-10-22 2011-11-04 Oreal USE OF ADENOSINE AND / OR ONE OF ITS DERIVATIVES AS A TREATMENT AGENT FOR HUMAN TRANSPIRATION
JP2013516471A (en) * 2010-01-06 2013-05-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Fatty acid derivatives and analogs of drugs
UY33245A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int TIENOPIRIMIDINES CONTAINING A SUBSTITUTED RENT GROUP FOR PHARMACEUTICAL COMPOSITIONS
AR080326A1 (en) 2010-02-26 2012-03-28 Boehringer Ingelheim Int TIENIPIRIMIDINES CONTAINING CYCLLOQUAL FOR PHARMACEUTICAL COMPOSITIONS
UY33241A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
EP2608794A4 (en) * 2010-08-26 2014-01-22 Univ Northeastern Methods and compositions for preventing or treating obesity
BR112014011254A2 (en) 2011-11-11 2017-05-16 Pfizer 2-thiopyrimidinones
EP3466959A1 (en) 2011-12-22 2019-04-10 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2597757T3 (en) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Uraciles pyroxexetane nucleosides
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
CN104884462A (en) * 2012-10-29 2015-09-02 共晶制药股份有限公司 Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
EA201590943A1 (en) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
KR20150100869A (en) 2012-12-28 2015-09-02 다우 아그로사이언시즈 엘엘씨 N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxamides derivatives
JP6324994B2 (en) 2012-12-28 2018-05-16 アダマ・マクテシム・リミテッド N- (substituted) -5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2H) -carboxylate derivative
AU2013370494B2 (en) 2012-12-31 2017-08-17 Adama Makhteshim Ltd. 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1H)-one derivatives as fungicides
PE20160658A1 (en) 2013-10-11 2016-08-05 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
KR102220260B1 (en) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
MA42035A (en) 2015-05-05 2018-03-14 Pfizer 2-THIOPYRIMIDINONES
CN109503587B (en) * 2017-09-14 2022-01-11 辽宁利锋科技开发有限公司 Anti-tumor effect and application of diheterocyclic triazole nucleoside analogue
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carbanucleoside using amide
CN113616657B (en) * 2021-08-02 2022-12-20 中山大学·深圳 Application of compound in preparation of medicine for treating and/or preventing demyelinating diseases
WO2023044104A1 (en) * 2021-09-17 2023-03-23 Emory University Phosphoramidates for the treatment of hepatitis b virus

Also Published As

Publication number Publication date
WO2004037159A2 (en) 2004-05-06
WO2004037159A3 (en) 2004-07-15
AU2003274652A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003274652A1 (en) Compounds, compositions and methods for modulating fat metabolism
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003270015A1 (en) Compounds, compositions, and methods
AU2003299612A1 (en) Compounds, compositions and methods
EP1503993A4 (en) Compounds, methods and compositions
HK1070656A1 (en) Compounds, compositions, and methods
AU2003252324A1 (en) Fat composition
AU2003219788A1 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1Alpha-
AU2003256805A1 (en) Compounds compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
AU2003287443A1 (en) Compositions and methods for pain reduction
AU2002950744A0 (en) Composition
AU2003280594A1 (en) Fat composition for spread
AU2002953359A0 (en) Microgel composition
AU2003290507A1 (en) Compounds, compositions and methods
AU2003277079A1 (en) Compounds, compositions, and methods
AU2003208411A1 (en) Anti-glycolytic composition
WO2003072064A9 (en) Methods and compositions for regulating adipogenesis
AU2003300031A1 (en) Compounds, compositions, and methods
AU2003267169A1 (en) Compounds, compositions and methods
AU2003212724A1 (en) Composition comprising phosphate
AU2002953252A0 (en) Compositions, Compounds and Methods for their Preparation
AU2003260555A1 (en) Shoe and means for tying same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase